Thai Patients' National List of Essential Medicines Category E(2) Access Situation: Hospital Data Evaluation
National List of Essential Medicines Access Situation
Keywords:
drug accessibility, national list essential medicine (NLEM), drug category E(2)Abstract
Drug accessibility to national list of essential medicines (NLEM) category E(2) is a key success indicator of public health system. The purpose of this research was to evaluate drug accessibility and outcomes in NLEM category E(2). This retrospective descriptive research was performed in Buddhachinaraj Phitsanulok Hospital, in patients who received drug between fiscal year 2008-2019. The percentage of drug accessibility was calculated from number of patients who had been diagnosed according to ICD-10 in indications of drug regulatory guidelines and received drug list E(2). Treatment outcome was evaluated from discharge status of patients. The results shown that top five drugs accessibility were bevacizumab 1,474 cases; peginterferon alfa-2a 1,244 cases; letrozole 365 cases; botulinum toxin type A 180 cases and docetaxel 165 cases. Drug accessibility was at 22.6% and all of health schemes could access to medicine. Top five drugs that improved symptoms or cured were erythropoietin alpha followed by intravenous immunoglobulin in four indications. The highest survival rate was found in imatinib in treatment of chronic myeloid leukemia (hazard ratio = 0.48, 95%CI 0.32-0.74, p = 0.0002). In conclusion, patients can access to expensive national list of drugs in E(2) if they meet conditions for diagnosis and follow drug regulatory guidelines.
References
2. National Drug List Development Committee. National Drug List 2008. Bangkok: Food and Drug Administration; 2009.
3. National Drug List Development Committee. National Drug List 2013. Bangkok: Food and Drug Administration; 2013.
4. National Drug List Development Committee. National Drug List 2018. Bangkok: Food and Drug Administration; 2018.
5. Cookson R, Hutton J. Regulating the economic evaluation of pharmaceuticals and medical devices: A European perspective.Health Policy 2003;63(2):167-78.
6. Davies L, Coyle D, Drummond M, on the Methodology TEN. Current status of economic appraisal of health technology in the European Community: Report of the network. Soc Sci Med 1994;38(12):1601-7.
7. Drummond M, Jonsson B, Rutten F. The role of economic evaluation in the pricing and reimbursement of medicines. Health Policy 1997;40(3):199-215.
8. Nason E, Husereau D. Round table on real world evidence system readiness-Are we ready to use routinely collected data to improve health system performance. Alberta, Canada: Institute on Health Economics;2014.
9. Turongkaravee S, Tantivaj S, Rattanavipapong W, Kamphang R, Leehawarong P, Teerawattananon Y. Evaluation of high-cost medicine scheme (Category E2) under the 2008 National List of Essential Medicines. Report No.4. Bangkok: Health Intervention and Technology Assessment Program, Ministry of Public Health; 2012.
10. Sruamsiri R, Wagner AK, Ross-Degnan D, Lu CY, Dhippayom T, Ngorsuraches S, et al. Expanding access to high-cost medicines through the E2 access program in Thailand: Effects on utilisation, health outcomes and cost using an interrupted time-series analysis. BMJ Open 2016;6(3):e008671. Available from: https://bmjopen.bmj.com/content/6/3/e008671.share
11. Patikorn C, Taychakhoonavudh S, Thathong T, Anantachoti P. Patient access to anticancer medicines under public health insurance schemes in Thailand: A mixed method study. Thai J Pharm Sci 2019;43(3):168-78.
12. Parkhurst J. The politics of evidence:From evidence-based policy to the good governance of evidence. New York:Routledge; 2017.
13. Asante AD, Zwi AB. Public-private partnerships and global health equity: Prospects and challenges. Indian J Med Ethics 2007;4(4):176-80.
14. Hawkins B, Parkhurst J. The good governance of evidence in health policy. Evid Policy 2016;12(4):575-92.
15. Department for International Development. Increasing access to essential medicines in the developing world: UK Government policy and plans. London: Department for International Development; 2004.
16. Singleton N, Rubin J. What is good governance in the context of drug policy?. Intern J Drug Policy 2014;25(5):935-41.
17. Krattiger AF, Mirza Z, Taubman A, Watal J. Promoting access to medical technologies and innovation: Intersections between public health, intellectual property and trade. Geneva:World Intellectual Property Organization;2013.
18. Kast K, Schoffer O, Link T, Forberger A, Petzold A, Niedostatek A, et al. Trastuzumab and survival of patients with metastatic breast cancer. Arch Gynecol Obstet 2017;296(2):303-12.
19. Bunn PA, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions. Clin Cancer Res 1998;4(5):1087-100.
20. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34(5):563-71.
